Trials / Completed
CompletedNCT04353869
Targeting Glutamine Metabolism to Prevent Diabetic Cardiovascular Complications
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 995 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Experimental data suggest that glutamine catabolism in involved in the activation of macrophages by generating TCA(Tricarboxylic acid) intermediates that promote the pro-inflammatory polarization of macrophages. The project investigates the possible link between glutaminolysis, monocytes polarization and diabetes related cardiovascular complications in humans
Detailed description
The aim of the study is to investigate the role of glutamine metabolism in the pro-inflammatory activation of macrophages in diabetes and related cardiovascular complications. The study focuses on 3 adult patients' population with different diabetic status and level of cardiovascular risk: * Patients with uncomplicated type 1 or type 2 diabetes and low cardiovascular risk * Patients with uncomplicated type 1 or type 2 diabetes and high cardiovascular risk * Patients with complicated type 1 or type 2 diabetes Participants (n=975) will be recruited at clinical sites, in the diabetes and cardiology departments (APHP, Bichat - Claude-Bernard Hospital and APHP, Lariboisière Hospital), over a 2-year period. The study will consist in a single visit. During a scheduled hospitalization or consultation as part of the follow-up of their diabetes or as part of the follow-up of their cardiological problems, clinical data will be collected as well as additional blood and urine samples for analyses and biobanking. There will be no other intervention specific to the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Bio collection | venous blood sampling and collection of urine |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2024-01-10
- Completion
- 2024-01-10
- First posted
- 2020-04-21
- Last updated
- 2025-03-05
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04353869. Inclusion in this directory is not an endorsement.